Immunization Newsbriefs (c) Copyright Information Inc.,
Bethesda, MD. Brought to you by the National Network for
Immunization Information (NNii). Visit NNii's new website at
http://www.immunizationinfo.org .
------------------------------------------------------------
August 7, 2002
U.S. IMMUNIZATION NEWS
"Priming of Human Papillomavirus Type 11-Specific Humoral and
Cellular Immune Responses in College-Aged Women With a Virus-Like
Particle Vaccine"
Journal of Virology Online ( jvi.asm.org ) (08/02) Vol. 76, No. 15,
P. 7832; Emeny, Rebecca T.; Wheeler, Cosette M.; Jansen, Kathrin
U.
A group of college-aged seronegative women was involved in a test
of a human papillomavirus (HPV) virus-like particle (VLP)-based
vaccine, given in intramuscular injections at zero months, two
months, and six months, with half the women receiving a final
dosage at 12 months. Specifically, the vaccine was tested on its
generation of HPV type 11-specific cellular and humoral immune
responses. All of the women showed a positive HPV type 11
VLP-specific lymphoproliferative response after the second
immunization and antibody titers after the first immunization.
Compared to women who were given a placebo, the immunized women
had a lymphoproliferative stimulation index 7.6 times higher
after the first immunization, including greater immune responses
from blood mononuclear cells. The responses were solely against
HPV type 11, as stimulation indexes against bovine papillomavirus
and HPV type 16 VLPs were as low after the immunization as they
had been before the event.
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.